Pharmaceutical and Biotech plants for sale
14M Euro EBITDA growing Biotech CDMO in North Europe for sale
Fast growing Contract development and manufacturing organization (CDMO) in North Europe established EU – cGMP certified manufacturing facility (3.500 metros cuadrados), R&D area including QC labs of D, C and B grade. Fast growing (94%+ 5 years CAGR) revenue 75% in USA, 17% en Europa, 7% in ROW, providing services to big pharma, small-mid biotech companies.
Operates in biopharmaceutical CDMO market, offers fully integrated services, starting from cell line construction and process development up to cGMP production of biopharmaceutical products (DS & DP). Ex-Teva Biopharmaceuticals TOP management,
135 well trained employees. Finanzas: 2016 annual revenue – 28M Euro, EBITDA – 8M Euro, 2017E annual revenue – 38M Euro, EBITDA – 14M Euro, 2018B annual revenue – 50M Euro,
EBITDA – 21M Euro.
18+ M Euro revenue profitable, growing ANVISA distributor in São Paulo, Brazil for sale
Based in São Paulo, Especializados en el campo de la otorrinolaringología y ortopedia., representa dos de los mayores proveedores globales con exclusividad en el mercado brasileño. Los clientes de la empresa son principalmente privados. (95%) con solo 5% de compradores gubernamentales. Its strategic position in the
Brazilian market is coupled by a solid image in the medical profession and clients with unblemished reputation and tradition for over 30 años. Ingresos anuales crecientes: 2016 – 14.7 millones de euros, EBITDA (26%) 3.8 millones de euros, 90 empleados, sin deudas, el efectivo neto 1.5 millones de euros. Motivación para la venta.: evaluar otros escenarios de negocios. Asking price 29 millones de euros ( 95 M Brazilian Real ).
13M+ USD revenue growing profitable Pharmaceutical Company for sale in Brazil
Empresa farmacéutica de propiedad privada con sede en Brasil que produce y comercializa productos farmacéuticos con sus propias marcas.. Planta aprobada por ANVISA, donde se ha registrado 31 productos. Ventas: Líquidos 62%, Sólidos 25%, Semisólidos 13%; Distribución de Ventas: cuerpos de cadetes militares – 37%, Fitofármacos – 29%, Drogas genericas – 17%, 42.500 m2 de espacio industrial recientemente adquirido y aprobado por ANVISA para uso industrial. Incentivos fiscales regionales: reducción de 75% of Income Tax
para 10 años, entre otros incentivos fiscales para los industriales. Ingresos 2016: 43.5 M Reales (13millones de dólares), EBITDA 2016: 4.7 M Reales (1.4 millones de dólares), 330 Empleados: CAGR de ventas 2006-2016 12%
11M+ Euro annual revenue profitable and growing specialty pharmaceutical company in Poland
Company is looking for a JV / strategic partner / investor to successfully continue company growth. Company strong in Dermatology (70% of portfolio), CNS (15%), the rest 15% are OTC and generics. Own Marketing Authorizations and brands, majority of the products are in-licensed from well know dossier owners / manufacturers.
Company do not have own manufacturing plant. 25+ brands, 70 empleados (55 reps) covering whole market. EBITDA 11%. Internal company valuation 28M Euro.
10M Euro revenue European fast growing company for sale
Ventas farmacéuticas de rápido crecimiento & grupo de marketing con ca. 20 empleados, cartera de productos de 150 productos Rx y OTC de alta calidad (en su mayoría expedientes CTD de la UE producidos en plantas GMP de la UE), categorías terapéuticas – sistema nervioso central, cardiovascular, oncología, gastroenterología, respiratorio, el manejo del dolor, osteoporosis, alergología, infectology, alrededor 600 Máster ya concedidos a nivel mundial, adicional 50 AM pendientes bajo procedimientos regulatorios en curso, main operations in
Alemania, también en los mercados de la UE: Reino Unido, Dinamarca, Polonia, Países Bajos, Portugal, Italia, España, otros y ventas internacionales en 33 países. Cooperar con fabricantes seleccionados de primer nivel en Europa y Asia. Licencia UE GMP y mayorista, Licencia de importación de la UE, sin bienes raíces, sin planta de producción, sin préstamos bancarios, sin obligaciones de pensiones. Carefully selected product portfolio potential to growth to 100+ M Euro in 2022. Finanzas: 10 M Euro revenue in 2017.
10M USD revenue, very profitable and growing Indian pharma company for sale ideal acquisition for companies willing to enter India market
Privately owned, HQ in Mumbai, fast growing pharmaceutical sales & marketing company in India with 350 field force and Top known brands over 20 years with great brand recall, 6 brands are #1 in the therapy areas. 350 field force covering
- 000 GP’s, 7.500 Gynecologists, 6.200 Physicians, 4.000 Ortho, 3.800 General Surgeons, 2.100 ENT, 1.000 Dentists. Production in own 2 GMP plants (which are not for sale) and distribution to 1.000 Distributors covering whole India pharmacies (29 states).
- Active in these therapy areas: Cephalosporin’s, Muscle Relaxant and Pain Management, Anti-ulcerants (PPI), Anti-diabetics, Anthelmintic, Spasm and Pain Management, Macrolides, Cough Syrup, Multivitamin Supplementation, Quinolone Combinations, Dermatological. Finanzas: 10 M USD Revenue, Gross Margin of 67%, 2.5M USD net profit, Asking price: ca. 30 M USD asking price (3x revenue, 12 profits)
8M Euro revenue pharmaceutical company for sale in North West Europe
La empresa gestiona el marketing., selling and distribution of pharmaceutical/medical supplies and devices in the several markets of North
Western Europe. El 8 millones de euros negocio en crecimiento y negocio rentable. Los productos farmacéuticos/dispositivos representados actualmente incluyen inyectables., infusiones, tabletas y dispositivos que abordan las áreas de manejo del dolor, women’s reproductive health, infección por hongos y afecciones de la tiroides.
Además de gestionar sus propios productos., La empresa también representa organizaciones internacionales que no tienen un marketing local., representante de ventas y distribucion. La empresa no tiene planta de producción propia.. Asking price 4M Euro
6M Euro pharmaceutical (dermatology) company in Italy for sale
Empresa farmacéutica italiana de propiedad privada fundada en 2000, enfocado en el campo de la dermatología. Las marcas fuertes se encuentran entre las más recomendadas por los dermatólogos en Italia. Gama de productos de cosmecéuticos., Dispositivos Médicos y Complementos Alimenticios para el tratamiento de diversas patologías dermatológicas. La Compañía cuenta con un equipo de 8 empleados: Un personal profesional altamente capacitado con experiencia sustancial y son promovidos por personal altamente calificado. 27 representantes de la fuerza de ventas (agentes exclusivos)
Finanzas: 2016 – 5.35Ingresos en millones de euros, 1.3Millones de euros EBITDA; 2017B – 6.0M Euro revenue, 1.4Millones de euros EBITDA; 24% Margen EBITDA; 15% annual revenue growth No debts
Asking price 11M Euro
3,5 M€ revenue GMP plant and products for sale in Italy
Italian company with local and international operations, own products, 3,5 M€ turnover, oral solids and liquids, producing pharmaceuticals and Medical devices, 35 empleados
Asset value: according to a recent evaluation the value of the building (manufacturing + warehouse + offices) is 7,3 M€ Debts total debts 3,4 M€
Running costs yearly in the range 4,2-4,5 M€ EBITDA 2016 < 0
Motivation for sale the owner is getting old and would like to retire. The sons are not interested in running the business being involved in other activities.
1.4Ingresos en millones de euros, profitable and modern Russian CMO with long term contracts for sale
Founded in 2011, State of the art, audited by TOP MNC pharma companies, CMO located in Moscow area with comfortable transport junction, Long-term contract manufacturing agreements (packaging) with 5+ TOP MNC pharmaceutical companies. Total area – 1.600 m2, including equipment stock, analytical laboratory and microbiological laboratory. CMO contracts includes primary and secondary packaging with the release control of the sterile solutions for injections in ampoules and syringes; Manufacturing capacities – 9 mln. pack. per year and used now 20%.
Possibility to expand production capacities to oral solid (tablets and capsules with the capacity of 2.5 bln. tab/caps. per year and/or non-sterile oral liquids.
The manufacturing site is approved by Russian GMP license and equipped with necessary communications and engineering equipment of the leading worldwide manufacturers including System for preparation, storage and distribution of purified water; Power supply system; Air preparation and conditioning system; Compressed air preparation and distribution system; Climatic parameter monitoring system; Security alarm and video monitoring system; Cooling-compressor equipment; Blister and cartooning machines. New equipment value app 1 M, land and building in on long term rent contract. 54 empleados, annual revenue 1.4 millones de euros, rentable, no loans from the banks.
1M+ Euro revenue Germany oncology company for sale
Empresa farmacéutica de propiedad privada., especializado en el campo de la oncología
(genéricos, parenteral), strong in the private sector market with clinical phase IV
studies. Five products actively marketed, four products to be launched.
Production is outsourced to well-known and reliable CMO’s. Supply chain is
secured. Licensor agreed to extend territory to pan EU, si se solicita. Ventas >€1m
Euro, rentable, EBITDA 15%.
Asking price 4.5x revenues
1M Euros ingresos Negocios hospitalarios en España en venta
La empresa registra y distribuye productos farmacéuticos de alta calidad. (agentes de contraste para rayos X, tomografía computarizada y resonancia magnética) en un acuerdo exclusivo; Posee TAC y Marcas propias para el mercado español y distribuye estos productos a los hospitales.. La compañía está a punto de lanzar una nueva generación de productos radiológicos en el mercado español, así como registrar y comercializar nuevos productos de diagnóstico oncológico 10 gente, 7 de los cuales son fuerza de ventas que cubren diferentes regiones. Aplicación de ingresos anuales. 1 millones de euros, margen bruto aproximadamente 55%.
0.5M Euro revenue EU GMP running injectable manufacturing plant in Spain for sale
CDMO rentable y en crecimiento (desarrollo de contrato & organización de fabricación) esta disponible para la venta. 15 empleados, propia tierra (5.000 metros cuadrados), edificio (2.000 metros cuadrados), equipo, sin deudas. Fabricación en envase de vidrio., contenedor de polipropileno, bolsas de polipropileno, soluciones de riego. Proporcionar servicios: i) Manufacturing of liquid parenteral solutions with terminal sterilization ii) Desarrollo y análisis galénico iii) Pruebas de estabilidad iv) Marketing, logística y distribución. Ventajas competitivas: i) tax incentives, ii) no hay préstamos para el activo iii) agua del suelo, IV) European machineries v) lower labor costs due to region. Asking price 5 millones de euros.
200 K Euro revenue HRT brand divestment in Germany
Máster y marca en Alemania en terapia de reemplazo hormonal (TRH) Para el alivio de las molestias durante o después de la menopausia, así como para la prevención de la osteoporosis.. Se vende un producto establecido y comercializado desde hace mucho tiempo., German MA granted – no limits, Sin fecha de caducidad + Marca comercial. Sin actividades de promoción unos ingresos anuales estables de 200.000 Euro. El producto está en la lista de reembolso.. Posibilidad de cooperar con CMO existente o producción propia por discutir. Hay existencias disponibles para una transacción comercial sin problemas..
US FDA approved operating plant for sale – Los Angeles
Located on East Cost, Manufacturing operation is approved by the US FDA. It has 43,800 square feet floor area consisting of Production, Production Services, embalaje, Warehouse & Dispensing, QC Labs, Maintenance& Utilities, Administration and office areas. Manufacturing Capacity: 1.5 Billion Tablets. The operating costs for the site (utilities, power and maintenance) are roughly $500K per year and expenses for 40
employees is 3 Million USD per year. A detailed break-up will be provided during the due diligence phase.
Object for sale is the land, edificio, equipment and other non-movable assets associated with the facility, running US FDA approved license. There will be no transfer of distribution licenses or any other licenses, no any products and no any services. This is a good as an entry for a company who can bring products/volumes himself. Asset value including land approx.. 10millones de dólares. Asking price 15M USD
US FDA approved operating plant for sale – project Virginia
Place and factory: 53 acres located in Virginia; 424K sq. a. (under roof), production and packaging; 167K sq. a. Warehouse; 124K sq. a. Production, 31K sq. a. QA/QC lab, 53K sq. a. Office/Admin, 450 parking spaces, Residential: property includes additional 10 acres with 4 residential houses. A divestment from MNC Company having 10+ factories, an opportunity to provide CMO services for 2-3 years for existing 56+ ANDA’s while technology transfer will be transferred to seller another factories. No products included in the business for sale. Employees and Production expenses:
320 highly trained employees, site production expenses USD 56.5 million for 2017. Capacity: up to 3B oral solid dosages manufacturing and up to 3.5B doses packaging, Non-potent, Potent (OHC 4-5) and DEA (CII- CV) controlled OSD products, Focusing primarily on US/ Canada markets
450M+ USD revenue growing and profitable global pharmaceutical company for sale
450M+ USD revenue profitable global generic pharmaceutical company for sale with 100M+ EBITDA, own products 200+ EU CTD dossiers, global business in 100+ países, 120 empleados, own production plants, acting in cardiovascular, respiratorio, CNS, gastroenterología, urología, other therapy areas.
160 M Euro revenue global cephalosporin products divestment
Products marketed in 100+ markets, 37% revenue in Europe, 30% APAC, 15% LATAM, 9% Oriente Medio 9% África. Full range of dosage forms covering sterile injectibles, oral tablets, paediatric suspension, integrated oral and sterile 3 manufacturing plants based in Europe approved by EMEA and FDA, 870 – total number of employees in the factories, experienced management and
manufacturing expertise will be transferred as part of the business. Additional revenue stream from growing CMO business.
